Ivospemin hydrochloride is a Small Molecule owned by Panbela Therapeutics, and is involved in 5 clinical trials, of which 2 were completed, 1 is ongoing, and 2 are planned.

Ivospemin hydrochloride (SBP-101, SUN-101) directly and specifically targets DNA replication in the acinar/ductal cells from which cancerous tumors in the pancreas typically emerge. Islet cells, which secrete insulin, are structurally and functionally dissimilar from acinar cells and are not impacted by SUN-101. The analogs enter cells through a selective poly-amine transport system and can be either poly-amine anti-metabolites that deplete the intracellular poly-amines or poly-amine mimetics that displace the natural poly amines from binding sites, but do not substitute in terms of growth-promoting function thus inhibiting the progression of disease.

The revenue for Ivospemin hydrochloride is expected to reach a total of $600m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Ivospemin hydrochloride NPV Report.

Ivospemin hydrochloride was originated by University of Florida and is currently owned by Panbela Therapeutics.

Ivospemin hydrochloride Overview

Ivospemin hydrochloride (SBP-101, SUN-101) is under development for the treatment of metastatic pancreatic ductal adenocarcinoma and recurrent acute or chronic pancreatitis, prostate cancer, pancreatic cancer and ovarian cancer. The drug candidate is an analog of polyamine (PA) and is administered through the subcutaneous route. It acts by targeting DNA synthesis.

It was also under development for colon cancer, breast cancer, lung cancer.

Panbela Therapeutics Overview

Panbela Therapeutics (Panbela), formerly Sun BioPharma Inc is a biopharmaceutical company. It develops disruptive therapeutics for the treatment of pancreatic cancer and pancreatitis. The company’s pipeline products include SBP-101. Its SBP-101 produces superior anti-tumour activity in human cancer cell lines and is used for the treatment of patients with pancreatic ductal adenocarcinoma, and pancreatitis. The company offers clinical trials and drug development services. It partners with institutions, cancer centres universities, and research centres for the development of drugs. Panbela is headquartered in Waconia, Minnesota, the US.

The operating loss of the company was US$10 million in FY2021, compared to an operating loss of US$5.7 million in FY2020. The net loss of the company was US$10.1 million in FY2021, compared to a net loss of US$4.8 million in FY2020.

Quick View – Ivospemin hydrochloride

Report Segments
  • Innovator
Drug Name
  • Ivospemin hydrochloride
Administration Pathway
  • Subcutaneous
Therapeutic Areas
  • Gastrointestinal
  • Oncology
Key Companies
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.